

PRESS RELEASE RELATED TO ANTIBIOTICE S.A.

Date: **03.03.2026**

Name of issuing company: **Antibiotice S.A.**

Headquarters: **lași, str. Valea Lupului nr. 1, zip code 707410**

<https://www.antibiotice.ro>

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **RO1973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

Critical medicines and biosimilars - the top priority of new investment projects at Antibiotice S.A.

This year, Antibiotice S.A. marks a new chapter in its strategic development by launching the “INOVA a+ Research & Development Center and production of critical medicines”, a project aimed at strengthening the company’s position in European pharmaceutical research and innovation. The investment represents an important step toward expanding the product development and validation capabilities, supporting the Antibiotice’s goal of delivering modern and competitive therapeutic solutions to both domestic and international markets.

We would like to remind that, in November 2025, Antibiotice S.A. signed jointly with the Ministry of Investments and European Projects (MIPE), the financing contract amounting to 75 million Euro for implementing the project “INOVA a+ Research & Development Center and production of critical medicines” funded through the Health Program - Priority 9 (Strategic Technologies for Europe Platform - STEP), with a completion deadline in 2029.

The research component of the project is represented by a new Inova a+ Research Center which will be built on the industrial site in Iași. This modern center will allow the expansion and diversification of critical medicine portfolio produced in Romania, in accordance with European priorities in the field, consolidating 125 highly specialized jobs. The Inova a+ Center will integrate modern laboratories, enabling high technology transfer in Romania. Antibiotice S.A. will address new research directions, facilitating development of biosimilar products used in the treatment of

serious conditions, including oncology therapies, sustainable synthesis of active substances through "green" processes and nanotechnology research for targeted medicine therapies.

The STEP project includes, in addition to the research component, investment in a modern production capacity for critical medicines in the form of sterile injectable β -lactam powders, filled into vials - a field in which Antibiotice has established expertise and European recognition for over 70 years. Until 2030, a production site for critical medicines under the form of sterile injectable powders, with a capacity of 100 million vials annually, will be built on the industrial site in Iași. Production of this new capacity will ensure both the need for critical medicines for hospitals in Romania and for healthcare systems at the European level.

Participation in the 4th edition of the EIB Group Forum

Between March 3-5, the Antibiotice representatives, together with its general Director, Mr. Ioan Nani are participating in the fourth edition of the EIB Group Forum, entitled "*A Strong Europe in a Changing World*". The event brings together European policymakers, business leaders and experts, addressing topics relevant to the current context, from security and defense to climate action and financing Europe's technological and industrial sovereignty.

Participation in this forum reconfirms Antibiotice's commitment to actively contribute to European strategic objectives of strengthening the resilience of health systems and developing critical industrial capabilities.

On this occasion, to the Head Office of the European Investment Bank, the Antibiotice team will hold discussions on the possible financing of the STEP program, as well as a consultancy component on main topics regarding the organization and monitoring of management activities with a decisive role in maximizing investment results.

Executiv Director Corporate Gouvernance,
Liviu VATAVU